[HTML][HTML] MHC class I downregulation in cancer: underlying mechanisms and potential targets for cancer immunotherapy
AM Cornel, IL Mimpen, S Nierkens - Cancers, 2020 - mdpi.com
In recent years, major advances have been made in cancer immunotherapy. This has led to
significant improvement in prognosis of cancer patients, especially in the hematological …
significant improvement in prognosis of cancer patients, especially in the hematological …
[HTML][HTML] MHC Class I Downregulation in Cancer: Underlying Mechanisms and Potential Targets for Cancer Immunotherapy
AM Cornel, IL Mimpen, S Nierkens - Cancers, 2020 - ncbi.nlm.nih.gov
In recent years, major advances have been made in cancer immunotherapy. This has led to
significant improvement in prognosis of cancer patients, especially in the hematological …
significant improvement in prognosis of cancer patients, especially in the hematological …
[PDF][PDF] MHC Class I Downregulation in Cancer: Underlying Mechanisms and Potential Targets for Cancer Immunotherapy
AM Cornel, IL Mimpen, S Nierkens - pdfs.semanticscholar.org
In recent years, major advances have been made in cancer immunotherapy. This has led to
significant improvement in prognosis of cancer patients, especially in the hematological …
significant improvement in prognosis of cancer patients, especially in the hematological …
MHC Class I Downregulation in Cancer: Underlying Mechanisms and Potential Targets for Cancer Immunotherapy
AM Cornel, IL Mimpen, S Nierkens - Cancers, 2020 - cir.nii.ac.jp
抄録< jats: p> In recent years, major advances have been made in cancer immunotherapy.
This has led to significant improvement in prognosis of cancer patients, especially in the …
This has led to significant improvement in prognosis of cancer patients, especially in the …
[PDF][PDF] MHC Class I Downregulation in Cancer: Underlying Mechanisms and Potential Targets for Cancer Immunotherapy
AM Cornel, IL Mimpen, S Nierkens - researchinformation.umcutrecht.nl
In recent years, major advances have been made in cancer immunotherapy. This has led to
significant improvement in prognosis of cancer patients, especially in the hematological …
significant improvement in prognosis of cancer patients, especially in the hematological …
MHC Class I Downregulation in Cancer: Underlying Mechanisms and Potential Targets for Cancer Immunotherapy
AM Cornel, IL Mimpen, S Nierkens - Cancers, 2020 - pubmed.ncbi.nlm.nih.gov
In recent years, major advances have been made in cancer immunotherapy. This has led to
significant improvement in prognosis of cancer patients, especially in the hematological …
significant improvement in prognosis of cancer patients, especially in the hematological …
MHC Class I Downregulation in Cancer: Underlying Mechanisms and Potential Targets for Cancer Immunotherapy.
AM Cornel, IL Mimpen, S Nierkens - Cancers, 2020 - europepmc.org
In recent years, major advances have been made in cancer immunotherapy. This has led to
significant improvement in prognosis of cancer patients, especially in the hematological …
significant improvement in prognosis of cancer patients, especially in the hematological …
MHC Class I Downregulation in Cancer: Underlying Mechanisms and Potential Targets for Cancer Immunotherapy.
AM Cornel, IL Mimpen, S Nierkens - Cancers, 2020 - search.ebscohost.com
In recent years, major advances have been made in cancer immunotherapy. This has led to
significant improvement in prognosis of cancer patients, especially in the hematological …
significant improvement in prognosis of cancer patients, especially in the hematological …
MHC Class I Downregulation in Cancer: Underlying Mechanisms and Potential Targets for Cancer Immunotherapy.
AM Cornel, IL Mimpen, S Nierkens - Cancers, 2020 - europepmc.org
In recent years, major advances have been made in cancer immunotherapy. This has led to
significant improvement in prognosis of cancer patients, especially in the hematological …
significant improvement in prognosis of cancer patients, especially in the hematological …